Abstract

We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 individuals across three molecular classes, metabolites, lipids and proteins. Homocitrulline, isoleucine and 2-aminoadipic acid, eight triacylglycerol species, and lowered sphingomyelin 42:2;2 levels are predictive of faster progression towards insulin requirement. Of ~1,300 proteins examined in two cohorts, levels of GDF15/MIC-1, IL-18Ra, CRELD1, NogoR, FAS, and ENPP7 are associated with faster progression, whilst SMAC/DIABLO, SPOCK1 and HEMK2 predict lower progression rates. In an external replication, proteins and lipids are associated with diabetes incidence and prevalence. NogoR/RTN4R injection improved glucose tolerance in high fat-fed male mice but impaired it in male db/db mice. High NogoR levels led to islet cell apoptosis, and IL-18R antagonised inflammatory IL-18 signalling towards nuclear factor kappa-B in vitro. This comprehensive, multi-disciplinary approach thus identifies biomarkers with potential prognostic utility, provides evidence for possible disease mechanisms, and identifies potential therapeutic avenues to slow diabetes progression.

There is an urgent need for biomarkers for type 2 diabetes progression that provide a deeper understanding of the disease process. Here, the authors identify biomarkers in three molecular classes, replicate them in other cohorts and explore top protein biomarkers in detail in functional studies.

Details

Title
Identification of biomarkers for glycaemic deterioration in type 2 diabetes
Author
Slieker, Roderick C. 1   VIAFID ORCID Logo  ; Donnelly, Louise A. 2 ; Akalestou, Elina 3 ; Lopez-Noriega, Livia 3 ; Melhem, Rana 4 ; Güneş, Ayşim 5 ; Abou Azar, Frederic 4 ; Efanov, Alexander 6 ; Georgiadou, Eleni 3   VIAFID ORCID Logo  ; Muniangi-Muhitu, Hermine 3 ; Sheikh, Mahsa 3 ; Giordano, Giuseppe N. 7   VIAFID ORCID Logo  ; Åkerlund, Mikael 7 ; Ahlqvist, Emma 7   VIAFID ORCID Logo  ; Ali, Ashfaq 8   VIAFID ORCID Logo  ; Banasik, Karina 9   VIAFID ORCID Logo  ; Brunak, Søren 9   VIAFID ORCID Logo  ; Barovic, Marko 10 ; Bouland, Gerard A. 11   VIAFID ORCID Logo  ; Burdet, Frédéric 12 ; Canouil, Mickaël 13   VIAFID ORCID Logo  ; Dragan, Iulian 12 ; Elders, Petra J. M. 14 ; Fernandez, Celine 7   VIAFID ORCID Logo  ; Festa, Andreas 15 ; Fitipaldi, Hugo 7   VIAFID ORCID Logo  ; Froguel, Phillippe 16   VIAFID ORCID Logo  ; Gudmundsdottir, Valborg 17   VIAFID ORCID Logo  ; Gudnason, Vilmundur 17   VIAFID ORCID Logo  ; Gerl, Mathias J. 18   VIAFID ORCID Logo  ; van der Heijden, Amber A. 14 ; Jennings, Lori L. 19   VIAFID ORCID Logo  ; Hansen, Michael K. 20   VIAFID ORCID Logo  ; Kim, Min 21 ; Leclerc, Isabelle 22 ; Klose, Christian 23 ; Kuznetsov, Dmitry 12 ; Mansour Aly, Dina 7 ; Mehl, Florence 12   VIAFID ORCID Logo  ; Marek, Diana 12 ; Melander, Olle 7 ; Niknejad, Anne 12 ; Ottosson, Filip 24   VIAFID ORCID Logo  ; Pavo, Imre 25 ; Duffin, Kevin 6 ; Syed, Samreen K. 6 ; Shaw, Janice L. 6 ; Cabrera, Over 6 ; Pullen, Timothy J. 26   VIAFID ORCID Logo  ; Simons, Kai 27 ; Solimena, Michele 28 ; Suvitaival, Tommi 8 ; Wretlind, Asger 8   VIAFID ORCID Logo  ; Rossing, Peter 29   VIAFID ORCID Logo  ; Lyssenko, Valeriya 30 ; Legido Quigley, Cristina 21 ; Groop, Leif 31   VIAFID ORCID Logo  ; Thorens, Bernard 32   VIAFID ORCID Logo  ; Franks, Paul W. 33   VIAFID ORCID Logo  ; Lim, Gareth E. 4 ; Estall, Jennifer 5   VIAFID ORCID Logo  ; Ibberson, Mark 12   VIAFID ORCID Logo  ; Beulens, Joline W. J. 34   VIAFID ORCID Logo  ; ’t Hart, Leen M 35   VIAFID ORCID Logo  ; Pearson, Ewan R. 2   VIAFID ORCID Logo  ; Rutter, Guy A. 36   VIAFID ORCID Logo 

 Amsterdam Public Health Institute, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUMC, Department of Epidemiology and Data Science, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 University of Dundee, Population Health & Genomics, School of Medicine, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876) 
 Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 CHUM Research Centre and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
 IRCM and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
 Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, US (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544) 
 Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 Steno Diabetes Center Copenhagen, Gentofte, Denmark (GRID:grid.419658.7) (ISNI:0000 0004 0646 7285) 
 Novo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
10  Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany (GRID:grid.507329.a) 
11  Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
12  Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland (GRID:grid.419765.8) (ISNI:0000 0001 2223 3006) 
13  Lille University Hospital, INSERM U1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845) 
14  Amsterdam Public Health Research Institute, Amsterdam UMC–location VUmc, Department of General Practice and Elderly Care Medicine, Amsterdam, the Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X) 
15  Eli Lilly Regional Operations GmbH, Vienna, Austria (GRID:grid.4514.4); LK Stockerau, 1st Medical Department, Niederösterreich, Austria (GRID:grid.4514.4) 
16  Lille University Hospital, INSERM U1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845); Endocrinology and Metabolism, Imperial College London, Division of Systems Biology, Department of Diabetes, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
17  University of Iceland, Faculty of Medicine, Reykjavik, Iceland (GRID:grid.14013.37) (ISNI:0000 0004 0640 0021); Icelandic Heart Association, Kopavogur, Iceland (GRID:grid.420802.c) (ISNI:0000 0000 9458 5898) 
18  Lipotype GmbH, Dresden, Germany (GRID:grid.420802.c) 
19  Novartis Institutes for Biomedical Research, Cambridge, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056) 
20  Janssen Research & Development, Cardiovascular and Metabolic Disease Research, Spring House, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927) 
21  Steno Diabetes Center Copenhagen, Gentofte, Denmark (GRID:grid.419658.7) (ISNI:0000 0004 0646 7285); Faculty of Life Sciences and Medicines, King’s College London, Institute of Pharmaceutical Science, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
22  Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); CHUM Research Centre and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
23  Lipotype GmbH, Dresden, Germany (GRID:grid.14848.31) 
24  Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Statens Serum Institut, Section for Clinical Mass Spectrometry, Danish Center for Neonatal Screening, Department of Congenital Disorders, Copenhagen, Denmark (GRID:grid.6203.7) (ISNI:0000 0004 0417 4147) 
25  Eli Lilly Regional Operations GmbH, Vienna, Austria (GRID:grid.6203.7) 
26  Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Guy’s Campus King’s College London, Department of Diabetes, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
27  Lipotype GmbH, Dresden, Germany (GRID:grid.13097.3c) 
28  Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany (GRID:grid.507329.a); University Hospital and Medical Faculty Carl Gustav Carus, Molecular Diabetology, TU Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257) 
29  Steno Diabetes Center Copenhagen, Gentofte, Denmark (GRID:grid.419658.7) (ISNI:0000 0004 0646 7285); University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
30  University of Bergen, Department of Clinical Science, Center for Diabetes Research, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Lund University Diabetes Centre, Skåne University Hospital, Genomics, Diabetes and Endocrinology Unit, Department of Clinical Sciences Malmö, Malmö, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987) 
31  Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Helsinki University, Finnish Institute of Molecular Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071) 
32  University of Lausanne, Center for Integrative Genomics, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204) 
33  Lund University, Department of Clinical Sciences, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Harvard School of Public Health, Department of Nutrition, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
34  Amsterdam Public Health Institute, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUMC, Department of Epidemiology and Data Science, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352) 
35  Amsterdam Public Health Institute, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location VUMC, Department of Epidemiology and Data Science, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); Leiden University Medical Center, Department of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
36  Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, Section of Cell Biology and Functional Genomics, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); CHUM Research Centre and University of Montreal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore (GRID:grid.59025.3b) (ISNI:0000 0001 2224 0361) 
Pages
2533
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2808772778
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.